JPRN-UMIN000013745已完成2 期
Phase II randomized trial of alendronate to compare oral and intravenous administration for bone mineral density in gastrectomized patients - Phase II randomized trial of alendronate to compare oral and intravenous administration for bone mineral density in gastrectomized patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who received local resection of the stomach 2. Patients who receive chemotherapy due to recurrent or remnant gastric cancer 3. Passage disturbance of esophagus due to achalasia or mechanical stenosis 4. Uncontrolled reflux esophagitis even by medication 5. Renal dysfunction or serum creatinine 1.5mg/dL or less 6. Scoliosis or compressed fracture of lumbar spine 7. Patients who received or plans extraction of tooth within three months 8. Previous treatment of bisphosphonate within six months 9. Patients who receive thyroid hormone or antithyroid hormone 10. Diabetes mellitus controlled by insulin 11. Patients who receive warfarin 12. Patients who receive any medication affecting bone metabolism. 13. Patients who have mental disorder or severe mental symptom 14. Allergy to the alendronate and vitamin D3 15. Other active malignancy occurring within 5 years before enrollment 16. Patients who are judged as inappropriate for study entry by the investigators
研究者
相似试验
进行中(未招募)
1 期
En randomiseret kontrolleret undersøgelse af alendronat som forebyggende behandling mod udvikling af glucocorticoid induceret osteoporose hos patienter der behandles for malignt lymfom.Age = 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens.Expected lifespan =2 yearsMedDRA version: 19.0Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2015-005688-18-DKDepartment of Hematology, Aalborg University Hospital60
已完成
不适用
Clinical study on efficacy of alendronate infusion for pediatric osteogenesis imperfecta (including severe form)osteogenesis imperfectaJPRN-UMIN000010615Tohoku University School of Medicine, Department of Pediatrics10
已完成
3 期
Alendronate effects in patients with lumbar spine fractureIRCT20101122005230N3Tabriz University of Medical Sciences60
已完成
2 期
Assessment of two doses of Alendronate on the treament of osteopenia on menopaused femalesOsteopenia.Menopausal and other perimenopausal disordersIRCT20190325043111N1Esfahan University of Medical Sciences140
已完成
2 期
The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected PatientsHIV InfectionsNCT00061256National Institute of Allergy and Infectious Diseases (NIAID)80
